Skip to content

Clinical and Prognostic Significance of Periodontitis in Patients With Arterial Hypertension

Clinical and Prognostic Significance of Periodontitis in Patients With Arterial Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07593768
Enrollment
200
Registered
2026-05-18
Start date
2023-10-10
Completion date
2026-05-30
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension, Periodontitis

Keywords

cardiovascular risk, arterial hypertension, inflammation, periodontitis

Brief summary

As part of a prospective study, to evaluate the effect of periodontitis on the course of hypertension at baseline, during 6 and 12 months

Detailed description

The study focuses on following tasks: to evaluate and compare arterial stiffness in patients with hypertension and the control group, the effect of treatment and control of clinical manifestations of periodontitis in patients with hypertension and the control group, the effect of treatment and control of clinical manifestations of periodontitis on the level of CRP in patients with hypertension and the control group, the effect of periodontitis control on the dynamics of OH, LDL, TG, uric acid, and fasting glycemia levels, the effect of periodontitis on the risk of atrial fibrillation/flutter in patients with arterial hypertension, to develop an information platform for patients with periodontitis for early detection of CVD risks and control of modifiable risk factors

Interventions

DIAGNOSTIC_TESTOrthopantomography

Orthopantomography

Sponsors

I.M. Sechenov First Moscow State Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age (18 years and older) * Written informed consent signed

Exclusion criteria

* Failure to follow up

Design outcomes

Primary

MeasureTime frameDescription
Triglyceride level12 months from inclusionTriglyceride level
Low density lipoprotein level12 months from inclusionLow density lipoprotein level

Countries

Russia

Contacts

PRINCIPAL_INVESTIGATOROlga Trushina, MD, PhD

Sechenov University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026